

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-16. (canceled).

17. (currently amended) A method of treating ~~or preventing~~ a disease or disorder ameliorated by the inhibition of PDE4 in a patient which comprises administering to a patient in need of such treatment ~~or prevention~~ a therapeutically ~~or prophylactically~~ effective amount of enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof.

18. (original) A method of controlling cAMP levels in a cell which comprises contacting a cell with an effective amount of enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide, or a pharmaceutically acceptable salt or solvate thereof.

19. (original) The method of claim 17, wherein the disease or disorder is depression, asthma, inflammation, inflammatory skin disease, psoriasis, atopic dermatitis, contact dermatitis, rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease, chronic pulmonary inflammatory disease, inflammatory bowel disease, Crohn's Disease, Bechet's Disease, colitis, chronic bronchitis, allergic rhinitis, arthritis, joint inflammation, ulcerative colitis, atopic eczema, stroke, bone resorption disease, multiple sclerosis, urticaria, allergic conjunctivitis, vernal conjunctivitis, inflammation of the eye, allergic responses in the eye, eosinophilic granuloma, gouty arthritis, arthritic condition, adult respiratory distress syndrome, diabetes insipidus, keratosis, cerebral senility, multi-infarct dementia, senile dementia, memory impairment associated with Parkinson's disease, cardiac arrest, intermittent claudication, rheumatoid spondylitis, osteoarthritis, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, cerebral malaria, silicosis, pulmonary sarcoidosis, reperfusion injury, graft vs host reaction, allograft rejection, infection-related fever, myalgia, malaria, HIV, AIDS, ARC,

cachexia, keloid formation, scar tissue formation, pyresis, systemic lupus erythematosus, type 1 diabetes mellitus, anaphylactoid purpura nephritis, chronic glomerulonephritis, leukemia, tarditive dyskinesia, yeast infection, fungal infection, condition requiring gastro protection, or neurogenic inflammatory disease associated with irritation or pain.

20-23. (canceled).

24. (currently amended) The method of any one of claims 17 to 19 further comprising administering to a patient in need of such treatment, ~~prevention~~ or control a therapeutically ~~or prophylactically~~ effective amount of an antihistamine, anti-inflammatory drug, non-steroid anti-inflammatory drug, steroid, anti-cancer agent, hematopoietic growth factor, cytokine, stem cell transplantation, or kinase inhibitor.

25. (original) The method of claim 17 wherein the disease or disorder is respiratory disease, asthma, allergic rhinitis, inflammation or chronic pulmonary inflammatory disease.

26. (original) The method of claim 17 wherein the disease or disorder is chronic obstructive pulmonary disease.

27. (previously presented) The method of claim 17 or 19 wherein the patient is a mammal.

28. (previously presented) The method of any one of claims 17 to 19 wherein the enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered parenterally, transdermally, mucosally, nasally, buccally, sublingually, topically, or orally.

29. (currently amended) The method of any one of claims 17 to 19 wherein the therapeutically ~~or prophylactically~~ effective amount is from about 1 mg to about 5,000 mg per day.

30. (currently amended) The method of claim 29 wherein the therapeutically ~~or prophylactically~~ effective amount is from about 10 mg to about 2,500 mg

per day.

31. (currently amended) The method of claim 30 wherein the therapeutically or ~~prophylactically~~ effective amount is from about 100 mg to about 1,200 mg per day.

32. (original) The method of claim 29, wherein the enantiomerically pure (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide is administered twice a day.

33-46. (canceled).